A new class of anti-HIV therapy and new challenges

New England Journal of Medicine

Volumn 359, Issue 14, 2008, Pages 1509-1511

  Dolin, Raphael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; LOPINAVIR; MARAVIROC; PROTEINASE INHIBITOR; RITONAVIR; TIPRANAVIR; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CYCLOHEXANE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; TRIAZOLE DERIVATIVE;

DRUG MECHANISM; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS TRANSMISSION; ANTIVIRAL RESISTANCE; DRUG ANTAGONISM; NOTE;

ANTI-RETROVIRAL AGENTS; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; TRIAZOLES;

EID: 54849146400     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0806598     Document Type: Editorial

References (13)

1. Kuhmann SE, Gulick RM, Moore JP. Inhibiting the entry of R5 and X4 HIV-1 phenotypic variants. In: Dolin R, Masur H, Saag M, eds. AIDS therapy. 3rd ed. Philadelphia: Churchill Livingstone, 2008:415-47.
2. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41.
3. Fätkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008;359:1442-55.
4. Selzentry (maraviroc). In: Physicians' desk reference. Vol. 62. Montvale, NJ: Thomson Healthcare, 2008:2540.
5. Trinh L, Han D, Huang W, et al. Technical validation of an enhanced sensitivity Trofile HIV co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Presented at the XVII International HIV Drug Resistance Workshop, Sitges, Spain, June 10-14, 2008.
6. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA panel. JAMA 2008;300:555-70.
7. Moreno C, Gustot T, Nicaise C, et al. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology 2005;42:854-62.
8. Nichols W, Steel H, Bonny T. Hepatotoxicity observed in clinical trials of aplaviroc (APL, 873140). Presented at the 10th European AIDS Conference, Dublin, November 17-20, 2005.
9. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006;203:35-40.
10. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001;357:1758-61.
11. Rusert P, Kuster H, Joos B, et al. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol 2005;79:8454-69.
12. Repits J, Oberg M, Esbjörnsson J, et al. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol 2005;86:2859-69.
13. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004;200:761-70.